A cost-effectiveness analysis of axillary node dissection in postmenopausal women with estrogen receptor-positive breast cancer and clinically negative axillary nodes

Surgery

Volumn 126, Issue 3, 1999, Pages 568-576

  Orr, R K ^a   Col, N F ^a   Kuntz, K M ^a  

^a Gibbs Cancer Center and Research Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; TAMOXIFEN;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CONTROLLED STUDY; FEMALE; HEALTH CARE COST; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; QUALITY ADJUSTED LIFE YEAR; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 0032875827     PISSN: 00396060     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-6060(99)70100-5     Document Type: Article

References (45)

1. NIH Consensus Conference Treatment of early-stage breast cancer JAMA 265 1991 391 394
2. B Cady MD Stone J. Wayne New therapeutic possibilities in primary invasive breast cancer Ann Surg 218 1993 338 349
3. MA Warmuth G Bowen LR Prosnitz L Chu G Broadwater B. Peterson Complications of axillary lymph node dissection for carcinoma of the breast: a report based on a patient survey Cancer 83 1998 1362 1368
4. B Fisher C Redmond ER Fisher M Bauer N Wolmark DL. Wickerman Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation N Engl J Med 312 1985 674 681
5. PP Lin DC Allison J Wainstock KD Miller WC Dooley N Friedman Impact of axillary lymph node dissection on the therapy of breast cancer patients J Clin Oncol 11 1993 1536 1544
6. TJ Smith BE Hillner CE. Desch Efficacy and cost-effectiveness of cancer treatment: rational allocation of resources based on decision analysis J Natl Cancer Inst 85 1993 1460 1474
7. AS Detsky IG. Naglie A clinician's guide to cost-effectiveness analysis Ann Intern Med 113 1990 147 154
8. JJ Albertini GH Lyman C Cox T Yeatman L Balducci N. Ku Lymphatic mapping and sentinel node biopsy in the patient with breast cancer JAMA 276 1996 1818 1822
9. DL. Morton Intraoperative lymphatic mapping and sentinel lymphadenectomy: community standard care or clinical investigation? Cancer J Sci Am 3 1997 328 330
10. K Dowlatshahi M Fan HC Snider FA. Habib Lymph node micrometastases from breast carcinoma: reviewing the dilemma Cancer 80 1997 1188 1197
11. FA Sonnenberg JR. Beck Markov models in medical decision making: a practical guide Med Decis Making 13 1993 322 338
12. BE Hillner TJ. Smith Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer: a decision-analysis model N Engl J Med 324 1991 160 168
13. Early Breast Cancer Trialists' Collaborative Group Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy Lancet 339 1992 1 15 71-85
14. BE Hillner TJ. Smith A model of chemotherapy in node-negative breast cancer J Natl Cancer Inst Monogr 11 1992 143 149
15. R Nissen-Meyer K Kjellgren B. Mansson Adjuvant chemotherapy in breast cancer Recent Results Cancer Res 80 1982 142 (abstract)
16. RJ Brooks SE Jones SE Samon Improved outcome with early treatment in an adjuvant breast cancer program Proc Am Soc Clin Oncol 2 1983 110 (abstract)
17. MJ Silverstein ED Gierson JR Waisman WJ Colburn P. Gamagami Predicting axillary node positivity in patients with invasive carcinoma of the breast by using a combination of T category and palpability J Am Coll Surg 180 1995 700 704
18. CL Carter C Allen DE. Henson Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases Cancer 63 1989 181 187
19. B. Cady The need to reexamine axillary lymph node dissection for invasive breast cancer Cancer 73 1994 505 508
20. AA Goodman AL. Mendez Definitive surgery for breast cancer performed on an outpatient basis Arch Surg 128 1993 1149 1152
21. National Center for Health Statistics Vital statistics of the United States, vol 2: mortality part A 1986 Dept of Health and Human Services (US) Washington Publication PHS 86-1101
22. MC Weinstein JE Siegel MR Gold MS Kamlet LB Russell the Panel on Cost-effectiveness in Health and Medicine Recommendations of the panel on cost-effectiveness in health and medicine JAMA 276 1996 1253 1258
23. PM Ravdin M DeLaurentiis T Vendely GM. Clark Prediction of axillary lymph node status in breast cancer patients by use of prognostic indicators J Natl Cancer Inst 86 1994 1771 1775
24. PL Choong CJS deSilva HJS Dawkins GF Sterrett P Robbins JM. Harvey Predicting axillary lymph node metastases in breast carcinoma patients Breast Cancer Res Treat 37 1996 135 149
25. A Barth PH Craig MJ. Silverstein Predictors of axillary lymph node metastases in patients with T1 breast carcinoma Cancer 79 1997 1918 1922
26. PM Ravdin M DeLaurentiis T Vendely GM. Clark Prediction of axillary lymph node status in breast cancer patients by use of prognostic indicators J Natl Cancer Inst 86 1994 1771 1775
27. RA Silliman L Balducci JS Goodwin FF Holmes EA. Leventhal Breast cancer care in old age: what we know, don't know, and do J Natl Cancer Inst 85 1993 190 199
28. BE Hillner TJ Smith CE. Desch Efficacy and cost-effectiveness of autologous bone marrow transplantation in metastatic breast cancer—estimates using decision analysis while awaiting clinical trial results JAMA 267 1992 2055 2061
29. SL Blair KE O'Shea RK. Orr Surgeon variability in treating nonpalpable breast cancer: surgical oncology as a value-added specialty Ann Surg Oncol 5 1998 28 32
30. RK. Orr The impact of prophylactic axillary node dissection on breast cancer survival—a Bayesian meta-analysis Ann Surg Oncol 6 1999 109 116
31. J. Hayward The significance of local control in the primary treatment of breast cancer Arch Surg 122 1987 1244 1247
32. AO Langlands RJ Prescott TA. Hamilton A clinical trial in the management of operable cancer of the breast Br J Surg 67 1980 170 174
33. H Johansen S Kaae T. Schiodt Simple mastectomy with postoperative irradiation versus extended radical mastectomy in breast cancer—a twenty-five year follow-up of a randomized trial Acta Oncol 29 1990 709 715
34. Cancer Research Campaign Working Party Cancer research campaign (King's/Cambridge) trial for early breast cancer: a detailed update at the tenth year Lancet 2 1980 55 60
35. Early Breast Cancer Trialists' Collaborative Group Effects of radiotherapy and surgery in early breast cancer N Engl J Med 333 1995 1444 1455
36. B Cady MD Stone JG Schuler R Thakur MA Wanner PT. Lavin The new era in breast cancer: invasion, size and nodal involvement dramatically decreasing as a result of mammographic screening Arch Surg 131 1996 301 308
37. AH Letton EM Mason BJ. Ramshaw Twenty-year review of a breast cancer screening project: ninety-five percent survival of patients with nonpalpable cancers Cancer 77 1996 104 106
38. V. Velanovich Axillary lymph node dissection for breast cancer: a decision analysis of T1 lesions Ann Surg Oncol 5 1998 131 139
39. D. Cyrlak Induced costs of low-cost screening mammography Radiology 168 1988 661 663
40. AP Legorreta RJ Brooks AN Leibowitz LJ. Solin Cost of breast cancer treatment—a 4-year longitudinal study Arch Intern Med 156 1996 2197 2201
41. BG Haffty D Fischer M Rose M Beinfield C. McKhann Prognostic factors for local recurrence in the conservatively treated breast cancer patient: a cautious interpretation of the data J Clin Oncol 9 1991 997 1003
42. D Krag D Weaver T Ashikaga F Moffat VS Klimberg C. Shriver The sentinel node in breast cancer—a multicenter validation study N Engl J Med 331 1998 941 946
43. KM McMaster AE Giuliano MI Ross DS Reintgen KK Hunt DR. Byrd Sentinel-lymph-node biopsy for breast cancer—not yet the standard of care N Engl J Med 339 1998 990 995
44. RJ. Epstein Does the breast cancer dollar make sense? Eur J Cancer 28 1992 486 491
45. JS. Spratt Decisions, interventions, outcomes, and cost in cancer control J Surg Oncol 59 1995 143 146